MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/cid/ciae369

Медицинская библиотека · Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025

Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group.

Borja-Tabora Charissa, Fernando LakKumar, Lopez Medina Eduardo, Reynales Humberto, Rivera Luis, Saez-Llorens Xavier, Sirivichayakul Chukiat, Yu Delia, Folschweiller Nicolas, Moss Kelley J, Rauscher Martina, Tricou Vianney, Zhao Yuan, Biswal Shibadas

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Dengue is an increasing threat to global health. This exploratory analysis evaluated the immunogenicity, safety, and vaccine efficacy (VE) of a live-attenuated tetravalent dengue vaccine (TAK-003) in participants enrolled in the phase 3 DEN-301 trial (NCT02747927), stratified by baseline age (4-5 years, 6-11 years, or 12-16 years).

METHODS

Participants were randomized 2:1 to receive 2 doses of TAK-003, administered 3 months apart, or placebo. Dengue serostatus was evaluated at enrolment. VE against virologically confirmed dengue (VCD) and hospitalized VCD; immunogenicity (geometric mean titers [GMTs]); and safety were evaluated per age group through ∼4 years postvaccination.

RESULTS

VE against VCD across serotypes was 43.5% (95% confidence interval [CI]: 25.3%, 57.3%) for 4-5 year-olds; 63.5% (95% CI: 56.9%, 69.1%) for 6-11 year-olds, and 67.7% (95% CI: 57.8%, 75.2%) for 12-16 year-olds. VE against hospitalized VCD was 63.8% (95% CI: 21.1%, 83.4%), 85.1% (95% CI: 77.1%, 90.3%), and 89.7% (95% CI: 77.9%, 95.2%), for the 3 age groups, respectively. GMTs remained elevated against all 4 serotypes for ∼4 years postvaccination, with no evident differences across age groups. No clear differences in safety by age were identified.

CONCLUSIONS

This exploratory analysis shows TAK-003 was efficacious in dengue prevention across age groups in children and adolescents 4-16 years of age living in dengue endemic areas. Relatively lower VE in 4-5 year-olds was potentially confounded by causative serotype distribution, small sample size, and VE by serotype, and should be considered in benefit-risk evaluations in this age group.

Для цитирования: Borja-Tabora Charissa, Fernando LakKumar, Lopez Medina Eduardo, Reynales Humberto, Rivera Luis, Saez-Llorens Xavier, Sirivichayakul Chukiat, Yu Delia, Folschweiller Nicolas, Moss Kelley J, Rauscher Martina, Tricou Vianney, Zhao Yuan, Biswal Shibadas. Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group.. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2025. DOI: 10.1093/cid/ciae369.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.